{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:56:08Z","timestamp":1774439768694,"version":"3.50.1"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Introduction Despite extremely high and seemingly rising prevalence of non-alcoholic fatty liver disease (NAFLD), awareness for this health condition is still low. In the present study we analyzed, if this is reflected in clinical routine for advanced diagnostic measures.<\/jats:p>\n                  <jats:p>Methods Retrospective data of 93 patients with histologically determined fibrosis stage and confirmed etiology was analyzed. Patients were grouped according to chronic liver disease alone (n=40), concomitant chronic liver disease and NAFLD (n=29), or NAFLD alone (n=24). Fibrosis stage and presence of cirrhosis were main outcome measures.<\/jats:p>\n                  <jats:p>Results Patients with NAFLD were significantly older and had significantly higher body mass index and CAP-values than patients with chronic liver disease. Significantly higher fibrosis stages were observed in patients with NAFLD than in those with chronic liver disease alone (p=0.003). Presence of cirrhosis was significantly higher in patients with NAFLD than in patients with chronic liver disease (p=0.01). This was not associated with a significantly different age distribution over fibrosis stages between chronic liver disease and NAFLD. Undergoing liver biopsy 10 years earlier could have possibly prevented progression to cirrhosis in up to 7 patients with NAFLD. This could have potentially saved 35,000 \u20ac yearly health care resources.<\/jats:p>\n                  <jats:p>Conclusion These findings suggest that the time course for development of liver fibrosis and cirrhosis is not fundamentally different between patients with NAFLD or with other chronic liver diseases. Higher rates of cirrhosis observed in patients with NAFLD could potentially be ameliorated by earlier diagnostic work-up and improved monitoring.\u00a0<\/jats:p>","DOI":"10.1055\/a-1960-4006","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T18:57:16Z","timestamp":1673290636000},"page":"29-36","source":"Crossref","is-referenced-by-count":1,"title":["Patients with NAFLD exhibit more advanced fibrosis in liver biopsy than patients with other chronic liver diseases"],"prefix":"10.1055","volume":"61","author":[{"given":"Lydia","family":"Rohr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lemmer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Henning","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[{"name":"Pathologie, Ruhruniversit\u00e4t, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodor","family":"Baars","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Manka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Canbay","sequence":"additional","affiliation":[{"name":"Medizinische Klinik, Universit\u00e4tsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-0015","authenticated-orcid":false,"given":"Jan-Peter","family":"Sowa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ruhr University Bochum, Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"09","key":"ref2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"S Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"11","key":"ref4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data","volume":"51","author":"R Loomba","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"50","key":"ref5","doi-asserted-by":"crossref","first-page":"e23506","DOI":"10.1097\/MD.0000000000023506","article-title":"Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis (NAFLD\/NASH) patients in Spain","volume":"99","author":"M Romero-Gomez","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.16016","article-title":"Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease","volume":"52","author":"A Canbay","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"08","key":"ref7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1055\/a-1402-1263","article-title":"Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population \u2013 An analysis based on health insurance data","volume":"59","author":"JT Stahmeyer","year":"2021","journal-title":"Z Gastroenterol"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?","volume":"76","author":"JV Lazarus","year":"2022","journal-title":"J Hepatol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"M Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31608","article-title":"Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study","author":"MT Long","year":"2020","journal-title":"Hepatology"},{"issue":"10","key":"ref14","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1002\/ijc.25797","article-title":"Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis","volume":"128","author":"J Ertle","year":"2011","journal-title":"Int J Cancer"},{"issue":"06","key":"ref15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"QM Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management","volume":"62","author":"S McPherson","year":"2015","journal-title":"J Hepatol"},{"issue":"18","key":"ref17","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3390\/ijerph16183415","article-title":"NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome","volume":"16","author":"V Rosato","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"14","key":"ref18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"G Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111","author":"A Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2017.08.001","article-title":"Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"22","author":"ZM Younossi","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"07","key":"ref21","first-page":"1592","article-title":"Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls","volume":"18","author":"H Hagstr\u00f6m","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MCG.0000000000001409","article-title":"Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases","volume":"55","author":"RJ Wong","year":"2021","journal-title":"J Clin Gastroenterol"},{"issue":"05","key":"ref23","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"P Bedossa","year":"2012","journal-title":"Hepatol Baltim Md"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"J Ludwig","year":"1980","journal-title":"Mayo Clin Proc Mayo Clin"},{"issue":"05","key":"ref25","first-page":"320","article-title":"From the metabolic syndrome to NAFLD or vice versa?","volume":"42","author":"E Vanni","year":"2010","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"05","key":"ref27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"M Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years","volume":"59","author":"VWS Wong","year":"2010","journal-title":"Gut"},{"issue":"11","key":"ref29","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/cells9112458","article-title":"Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence","volume":"9","author":"G Mazzolini","year":"2020","journal-title":"Cells"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s00394-022-02846-7","article-title":"Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients","volume":"61","author":"M Bischoff","year":"2022","journal-title":"Eur J Nutr"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4093\/dmj.2022.0048","article-title":"Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease","volume":"46","author":"XL Zhang","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"10","key":"ref32","first-page":"2317","article-title":"Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease","volume":"20","author":"S Lefere","year":"2022","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"04","key":"ref33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0041-1731704","article-title":"Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review","volume":"41","author":"A Hashem","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.numecd.2022.01.024","article-title":"Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial","volume":"32","author":"D Noto","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"03","key":"ref35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review","volume":"160","author":"ZM Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"05","key":"ref36","first-page":"984","article-title":"Knowledge of liver fibrosis stage among adults with NAFLD\/NASH improves adherence to lifestyle changes","volume":"42","author":"P Carrieri","year":"2022","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"07","key":"ref37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"M Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.11.038.","article-title":"An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD","author":"GEH Lim","year":"2021","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"15","key":"ref39","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.3390\/jcm11154394","article-title":"Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4","volume":"11","author":"K John","year":"2022","journal-title":"J Clin Med"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1960-4006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T22:50:58Z","timestamp":1764111058000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1960-4006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,9]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1960-4006","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}